Around 70% of all breast cancers are estrogen receptor alpha positive and hence their development is highly dependent on estradiol. While the invention of endocrine therapies has revolusioned the treatment of the disease, resistance to therapy eventually occurs in a large number of patients. This paper seeks to illustrate and discuss the complexity and heterogeneity of the mechanisms which underlie resistance and the approaches proposed to combat them. It will also focus on the use and development of methods for predicting which patients are likely to develop resistance.
Zheng, L. H., Zhao, Y. H., Feng, H. L., & Liu, Y. J. (2014). Endocrine resistance in breast cancer. Climacteric, 17(5), 522–528. https://doi.org/10.3109/13697137.2013.864268